The American College of Rheumatology (ACR) told CMS in a letter this week that short-term, limited-duration insurance plans could reduce or restrict access to crucial care for people living with rheumatic diseases.
The American College of Rheumatology (ACR) told CMS in a letter this week that short-term, limited-duration insurance (STLDI) plans could reduce or restrict access to crucial care for people living with rheumatic diseases.
In February, the Trump administration proposed a rule that would extend the time that Americans can remain in STLDI plans from 3 months to 12 months. The administration says that the change will provide affordable coverage options to individuals and families who cannot afford plans that meet Affordable Care Act requirements, including some essential health benefits and protections for people who have preexisting health conditions.
“We recognize that extending coverage from [3] months up to [12] months may provide some individuals with more gap coverage than previously available, but we do not believe this coverage would provide benefits that most rheumatology patients need,” wrote David I. Daikh, MD, PhD, president of ACR, in the letter.
Furthermore, the letter argued that 12-month STLDI plans could create confusion for patients, as these plans may be mistaken for 12-month major coverage plans. Should CMS forge ahead with STLDI plans, ACR called for a requirement to disclose to consumers that essential health benefits that may not be included in a STLDI plan. It also asked that consumer-oriented price information—including such statements as “If you develop a disease or condition during this coverage period, you may not be eligible for benefits such as specialty drugs for rheumatoid arthritis that afflicts 1% of Americans and which can cost $58,000 per year”—be included in each STLDI plan’s information, and that consumer-friendly tables clearly identify differences between plans by noting the qualities of individual plans that are not features of STLDI plans.
ACR also asked CMS to carefully consider the question of how younger, healthier enrollees leaving the exchanges to purchase STLDI plans would affect the insurance market’s stability, and whether the exit of such enrollees could lead to higher premiums for patients with rheumatic diseases, compounding problems with affordability and access that this patient population already faces.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.